KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Payables (2016 - 2025)

Astrazeneca (AZN) has 3 years of Payables data on record, last reported at $25.3 billion in Q4 2025.

  • For Q4 2025, Payables rose 594.51% year-over-year to $25.3 billion; the TTM value through Dec 2025 reached $25.3 billion, up 594.51%, while the annual FY2025 figure was $25.3 billion, 594.51% up from the prior year.
  • Payables reached $25.3 billion in Q4 2025 per AZN's latest filing, up from $3.6 billion in the prior quarter.
  • Across five years, Payables topped out at $25.3 billion in Q4 2025 and bottomed at $3.6 billion in Q4 2024.
  • Average Payables over 3 years is $17.1 billion, with a median of $22.4 billion recorded in 2023.
  • Peak YoY movement for Payables: tumbled 83.73% in 2024, then surged 594.51% in 2025.
  • A 3-year view of Payables shows it stood at $22.4 billion in 2023, then crashed by 83.73% to $3.6 billion in 2024, then soared by 594.51% to $25.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $25.3 billion in Q4 2025, $3.6 billion in Q4 2024, and $22.4 billion in Q4 2023.